Big Pharma's Hunger for Biotech Drugs
from Massachusetts Biotechnology Council
This event has passed.
Wednesday, September 17, 2008, 8:00am - 10:00am
Sirtris Pharmaceuticals (formerly NASDAQ:SIRT) is focused on discovering and developing medicines with the potential to treat diseases associated with aging. Sirtris' drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by modulation of sirtuins, a recently discovered family of enzymes associated with the aging process.
Sirtris is currently engaged in clinical trials in patients with Type 2 Diabetes and MELAS, a mitochondrial disorder. In June 2008, GlaxoSmithKline (GSK) announced that it completed its acquisition of Sirtris for approximately $720 million. The company's headquarters remain in Cambridge, Massachusetts. Through the acquisition of Sirtris, GSK has significantly enhanced its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins.
Dr. Christoph Westphal will provide insights into what led to the acquisition and why it made sense for shareholders.
More information...
Pingbacks ( Use this URL to link to this event: http://www.marksguide.com/event/6557/ )
